Cargando…
A HER2-targeted antibody-novel DNA topoisomerase I inhibitor conjugate induces durable adaptive antitumor immunity by activating dendritic cells
We designed and developed a novel DNA topoisomerase I inhibitor MF-6, which was a more potent cytotoxin and a more potent inducer of immunogenic cell death compared with DXd. To utilize MF-6’s ability to induce antitumor immunity, a human epidermal growth factor receptor 2 (HER2)-targeted antibody–d...
Autores principales: | Tan, Xiaoding, Fang, Peng, Li, Kaiying, You, Meng, Cao, Yuxia, Xu, Hui, Zhu, Xiaohong, Wang, Lu, Wei, Xin, Wen, Haiying, Li, Wendi, Shi, Lei, Sun, Xiaowei, Yu, Dongan, Zhu, Huikai, Wang, Zhenzhen, Liu, Datao, Shen, Hui, Zhou, Wei, An, Maomao |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Taylor & Francis
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10269389/ https://www.ncbi.nlm.nih.gov/pubmed/37314961 http://dx.doi.org/10.1080/19420862.2023.2220466 |
Ejemplares similares
-
Preclinical Evaluation of 9MW2821, a Site-Specific Monomethyl Auristatin E–based Antibody–Drug Conjugate for Treatment of Nectin-4–expressing Cancers
por: Zhou, Wei, et al.
Publicado: (2023) -
Generation of a novel Antibody-Drug Conjugate targeting endosialin: potent and durable antitumor response in sarcoma
por: Capone, Emily, et al.
Publicado: (2017) -
The antitumor activity of CYB-L10, a human topoisomerase IB catalytic inhibitor
por: Yu, Qian, et al.
Publicado: (2019) -
Association Between the HER2 Protein Expression Level and the Efficacy of Neoadjuvant Chemotherapy in HER2-Positive Breast Cancer
por: Yan, Hui, et al.
Publicado: (2020) -
The Potential of Topoisomerase Inhibitor-Based Antibody–Drug Conjugates
por: Han, Seungmin, et al.
Publicado: (2022)